Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 9, 2005, Pages 3601-3606

  Dzinjalamala, Fraction K ^a,b   Macheso, Allan ^c   Kublin, James G ^d   Taylor, Terrie E ^b,e   Barnes, Karen I ^a   Molyneux, Malcolm E ^f   Plowe, Christopher V ^d   Smith, Peter J ^a,g  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF MALAWI   (Malawi)

^c MINISTRY OF HEALTH   (Malawi)

^d University of Maryland School of Medicine Center for Vaccine Development   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

^f MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

FANSIDAR; FOLIC ACID;

AGE DISTRIBUTION; ARTICLE; CHILD; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; FOLIC ACID BLOOD LEVEL; GENE MUTATION; GENOTYPE; HUMAN; IN VIVO STUDY; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALAWI; MALE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; VALIDATION PROCESS;

ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALAWI; MALE; MULTIVARIATE ANALYSIS; MUTATION; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFADOXINE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 24144444096     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.9.3601-3606.2005     Document Type: Article

References (20)

1. Bustos, D. G., J. E. Lazaro, F. Gay, A. Pottier, C. J. Laracas, B. Traore, and B. Diquet. 2002. Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. Trop. Med. Int. Health 7:584-591.
2. Chulay, J. D., W. M. Watkins, and D. G. Sixsmith. 1984. Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 33:325-330.
3. Hellgren, U., C. M. Kihamia, Y. Bergqvist, M. Lebbad, Z. Premji, and L. Rombo. 1990. Standard and reduced doses of sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum in Tanzania, with determination of drug concentrations and susceptibility in vitro. Trans. R. Soc. Trop. Med. Hyg. 84:469-473.
4. Hyde, J. E. 1990. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol. Ther. 48:45-59.
5. Kublin, J. G., F. K. Dzinjalamala, D. D. Kamwendo, E. M. Malkin, J. F. Cortese, L. M. Martino, R. A. G. Mukadam, S. J. Rogerson, A. G. Lescano, M. E. Molyneux, P. A. Winstanley, P. Chimpeni, T. E. Taylor, and C. V. Plowe. 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 185:380-388.
6. Mansor, S. M., V. Navaratnam, M. Mohamad, S. Hussein, A. Kumar, A. Jamaludin, and W. H. Wernsdorfer. 1989. Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. Br. J. Clin. Pharmacol. 27:381-386.
7. Mayxay, M., K. Chotivanich, S. Pukrittayakamee, P. Newton, S. Looareesuwan, and N. J. White. 2001. Contribution of humoral immunity to the therapeutic response in falciparum malaria. Am. J. Trop. Med. Hyg. 65:918-923.
8. Panisko, D. M., and J. S. Keystone. 1990. Treatment of malaria-1990. Drugs 39:160-189.
9. Plowe, C. V., J. F. Cortese, A. Djimde, O. C. Nwanyanu, W. M. Watkins, P. A. Winstanley, J. G. Estrada-Franco, R. E. Mollinedo, J. C. Avila, J. L. Cespedes, D. Carter, and O. K. Doumbo. 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J. Infect. Dis. 176:1590-1596.
10. Schapira, A., I. C. Bygbjerg, S. Jepsen, H. Flachs, and M. W. Bentzon. 1986. The susceptibility of Plasmodium falciparum to sulfadoxinc and pyrimethamine: correlation of in vivo and in vitro results. Am. J. Trop. Med. Hyg. 35:239-245.
11. Turner, P., and A. Richens. 1978. Clinical pharmacology, 3rd ed. Churchill Livingstone, Edinburgh, United Kingdom.
12. USP DI. 1995. Drug information for the health care professional, 15th ed., vol. 1. The United States Pharmacopeial Convention, Inc., Rockville, Md.
13. van Hensbroek, M. B., S. Morris-Jones, S. Meisner, S. Jaffar, L. Bayo, R. Dackour, C. Phillips, and B. M. Greenwood. 1995. Iron, hut not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 89:672-676.
14. Wang, P., M. Read, P. F. Sims, and J. E. Hyde. 1997. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol. Microbiol. 23:979-986.
15. Watkins, W. M., E. K. Mberu, P. A. Winstanley, and C. V. Plowe. 1997. The efficacy of antimalarial combinations in Africa: a predictive model based on pharmacokinetic and pharmacodynamic analysis. Parasitol. Today 13:459-464.
16. Weidekamm, E., H. Plozza-Nottebrock, I. Forgo, and U. C. Dubach. 1982. Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull. W. H. O. 60:115-122.
17. Weidekamm, E., D. E. Schwartz, U. C. Dubach, and B. Weber. 1987. Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. Chemotherapy 33:259-265.
18. White, N. J. 2003. Malaria, p. 1244. In G. C. Cook and A. Zumla (ed.), Manson's tropical diseases, 21st ed. Elsevier Science Limited, Edinburgh, United Kingdom.
19. Winstanley, P. A., W. M. Watkins, C. R. J. C. Newton, C. Nevill, E. Mberu, P. A. Warns, C. M. Waruiru, I. N. Mwangi, D. A. Warrell, and K. Marsh. 1992. The disposition of oral and intramuscular pyrimethamine/sulfadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. Br. J. Clin. Pharmacol. 33:143-148.
20. World Health Organization. 2002. Monitoring antimalarial resistance. Report of a W.H.O. consultation. W.H.O./CDS/CSR/EPH/2002.17. Geneva, Switzerland.